You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


FDA approves new dosing option for AZ’s Imfinzi

The US Food and Drug Administration (FDA) has approved AstraZeneca’s (AZ) checkpoint inhibitor Imfinzi for an additional dosing option.